Relay Therapeutics Inc. (RLAY) News
Filter RLAY News Items
RLAY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RLAY News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RLAY News From Around the Web
Below are the latest news stories about RELAY THERAPEUTICS INC that investors may wish to consider to help them evaluate RLAY as an investment opportunity.
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT. The presentation will be webcast live and may be accessed th |
Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from […] |
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the UpgradeRelay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Relay Therapeutics, Inc. (RLAY): A Bull Case TheoryWe came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Substack by Steve Wagner | Invest. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc. (RLAY)’s share was trading at $4.78 as of Dec 12th. Relay Therapeutics (RLAY) has unveiled promising interim data for RLY-2608, its groundbreaking allosteric PI3Kα inhibitor, […] |
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free SurvivalNew interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 |
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer SymposiumCompany to host conference call on Wednesday, December 11, 2024 at 7am ETCAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be pre |
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Relay Therapeutics price target lowered to $18 from $19 at LeerinkLeerink analyst Christopher Liu lowered the firm’s price target on Relay Therapeutics (RLAY) to $18 from $19 and keeps an Outperform rating on the shares after the company announced that lirafugratinib will be out licensed to Elevar Therapeutics. Recall, the company had previously announced its decision to seek a global commercial partner for lirafugratinib during a company event in September 2024. Overall, Leerink thinks this decision is a prudent use of resources given the relatively small siz |
Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now?We recently published a list of 10 Best All-Time Low Stocks To Buy Right Now. In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against other best all-time low stocks to buy right now. With November coming to a close, while markets are focused on the future […] |
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid TumorsGlobal licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in u |